Three experts bring targeted treatment strategies to help precise anti -cancer!

With the birth of molecular targeted therapy, lung cancer treatment models corresponding to different gene mutations are also continuously developing. Up to now, EGFR, ALK, RET, Braf, ROS1, NTRK, MET, and KRAS inhibitors have appeared. Many of them have become patients with non -small cell lung carcinoma (NSCLC) patients with positive genetic positive genes of genes. Standard treatment plan.

01

Treatment of targeted therapy, as well as drug resistance?

EGFR gene mutation is one of the common mutations of non -small cell lung cancer. For patients with EGFR mutations positive non-small cell lung cancer, using EGFR-TKIS has become a first-line treatment plan recommended by many guidelines, but many patients usually have drug tolerance for about 1 year. [1] When patients have developed diseases due to drug resistance, their original targeted drugs can not only continue to exert their curative effects. The progress of primary tumors, especially the progress of the brain, will have a significant impact on the prognosis of the patient.

At present, for patients with lung cancer who have obtained drug resistance, their main treatment methods are new target suppression for drug resistance. For example, patients with resistance to the first and second-generation EGFR-TKIS It can be treated with the third-generation EGFR-TKI, which can delay the progress of the disease through this treatment method. Some patients did not find new drug -resistant targets after drug resistance, or non -targeted drugs. At this time, the treatment plan may have to return to traditional chemotherapy.

For this reason, many friends even have "drug resistance" anxiety. Why do targeting therapy generally occur? Is there a way to delay the occurrence of drug resistance? If you want to get the answers to these questions, you must first understand the mechanism of drug resistance.

02

Drug resistance is not terrible. Experts teach you how to delay medicine!

It is currently believed that the mechanism that leads to EGFR-TKIS resistance can be divided into primary resistance and secondary drug resistance.

Primary resistance: refers to the patient's own existence of (EGFR) target mutations, but due to the natural existence of other (KRAS) gene mutations, this leads to the poor treatment effect of EGFR-TKI, and it is very fast.

Secondary resistance: During the treatment of targeting drugs, due to the continuous suppression of the target signaling pathway, the tumor develops other gene mutations in order to avoid the effect of drugs. Other mutations will inhibit the therapeutic effect of targeting drugs on targets, so as to thus Causes drug resistance. Including: EGFR secondary mutation, bypass pathway activation, historical transformation, tumor cell glucose decrease, and cell cycle -related gene mutations.

Picture source: reference [2]

Reproductive resistance during targeted treatment is the main cause of the progress of the disease. How to treat after drug resistance is the difficulty that needs to be overwhelmed at present.

At the same time, how to delay drug resistance is also a question worth exploring. Such as the use of old drugs combined with targeted drugs, or targeted therapy combined with other treatment methods, such as EGFR-TKIS combined with chemotherapy, surgery, immunotherapy, and so on.

In order to help you solve the anxiety of drug resistance and delay the occurrence of drug resistance as much as possible, under the guidance of the Science Professional Committee of the China Anti -Cancer Association, the tenth live broadcast of the 2022 "Pulmonary Power" was opened. Raiders: You must know these points before using drugs. "

In this live broadcast, we are very honored to invite the following three lung cancer experts:

Professor Founder from Shanghai Long March Hospital Respiratory and Critical Medicine Department;

Professor Zhang Huibiao from East China Hospital affiliated to Fudan University; Professor Zhang Huibiao;

Professor Sun Qinying from Shanghai Changhai Hospital breathing and critical condition.

Live theme

In this live broadcast, Professor Founder will discuss how to delay targeting drug resistance with friends? Professor Zhang Huibiao and Professor Sun Qinying will also explain "how to do lung cancer gene test" and "targeted therapy" around targeted therapy. Let everyone have no doubts on the road of targeted therapy and drive away anxiety.

If you want to know more about targeted therapy, you will quickly lock this live broadcast. The lung Xiaofan looks forward to everyone in the live broadcast room.

Live information

Live broadcast time

September 19: 00-21: 00

Live appointment

Method 1: China Anti -Cancer Association ’s popular science public account“ Tumor Good Doctor ”public welfare science popularization channel, make appointments to watch.

Method 2: Click to read the original text at the end of the text.

Expert Introduction

Professor Fang

Shanghai Long March Hospital Chief physician

Member of the Shanghai Respiratory Branch of the Chinese Medical Association;

Professional specialty: diagnosis and treatment of lung infection, diagnosis of lung cancer and comprehensive treatment, interventional diagnosis and treatment of bronchoscopy, internal medical thoracoscopy diagnosis and pleural disease

Scientific research specialty: The scientific research funds that have been undertaken include 2 National Natural Science Foundation of China and 1 Fund of Shanghai Science and Technology Commission. 2 articles

Professor Zhang Huibiao

Deputy Chief Physician at East China Hospital Affiliated to Fudan University

Assistant at Fudan University Institute of chest tumor research is good at minimally invasive surgery of chest diseases.

At the same time, you have accumulated rich experience in chemotherapy, targeted therapy, and immunotherapy of chest tumors.

He published more than 10 clinical research papers in well -known domestic and foreign magazines at home and abroad, and participated in the writing of 2 medical monographs. Participate in many scientific research funds.

Professor Sun Qinying

Shanghai Changhai Hospital Deputy Chief Physician of Respiratory and Critical Critical Medicine Division is currently the executive member of the Shanghai Anti -Cancer Society of Anti -Cancer Society

Participate in the work and publish more than 10 articles, of which 5 are published in foreign academic journals;

Participate in 6 professional specialties: diagnosis and treatment of lung nodule, lung cancer, diagnosis and treatment of dystopia, intervention therapy under bronchial mirrors, and system diagnosis and treatment of chronic airway diseases (asthma, slow pulmonary block) 2016.5 to 2018.5

The Department of Environmental Engineering, the Department of Environmental Engineering, Hopkins University of Hopkins University, Chinese Editorial Committee

references

[1]. Huang Xiaxia, Wang Hong. Epidermal growth factor receptor gene mutation of non-small cell lung cancer targeted therapy and its drug resistance mechanism. Chinese lung cancer magazine, 2022, 25 (3): 183-192.

. Published 2020 DEC 18.

- END -